CDER Says Keeping Avastin Breast Cancer Claim Would Undermine Accelerated Approval Process

FDA's Center for Drug Evaluation and Research intends to argue at a June hearing that the accelerated approval system will operate as a lower standard if bevacizumab's breast cancer indication is maintained while Genentech conducts another confirmatory trial.